Free Trial
LON:FAB

Fusion Antibodies (FAB) Share Price, News & Analysis

Fusion Antibodies logo
GBX 6.30 -0.40 (-5.97%)
As of 03:22 AM Eastern

About Fusion Antibodies Stock (LON:FAB)

Key Stats

Today's Range
6.30
6.62
50-Day Range
6.37
9.50
52-Week Range
2.80
12
Volume
4,454 shs
Average Volume
1.29 million shs
Market Capitalization
£5.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue. The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation. Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process. The global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021.

Remove Ads
Receive FAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fusion Antibodies and its competitors with MarketBeat's FREE daily newsletter.

FAB Stock News Headlines

The unusual signal flashing green again
Something fascinating happened in April... While a lot of Wall Street institutions were opening new positions in a falling stock, something different showed up on my screen. A special set of candles had just turned green - signaling the kind of momentum surge I'd seen only a handful of times before. What happened next? The stock soared 45% on the underlying stock in just a few weeks and 227% for anyone who traded the options. Naturally, there would have been smaller wins and those that would not have worked out, but this wasn't some penny stock or crypto play… It was ARM Holdings - a major semiconductor player that had just shed 9% of its value.
Fusion Antibodies Share Chat (FAB)
Fusion Antibody Share Chat (FAB)
See More Headlines

FAB Stock Analysis - Frequently Asked Questions

Fusion Antibodies' stock was trading at GBX 7.16 at the beginning of 2025. Since then, FAB shares have decreased by 12.0% and is now trading at GBX 6.30.
View the best growth stocks for 2025 here
.

Fusion Antibodies plc (LON:FAB) released its earnings results on Tuesday, November, 19th. The company reported ($0.80) earnings per share for the quarter. Fusion Antibodies had a negative net margin of 195.95% and a negative trailing twelve-month return on equity of 137.11%.

Shares of FAB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fusion Antibodies investors own include 4D pharma (DDDD), Omega Diagnostics Group (ODX), Tullow Oil (TLW), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP) and Coats Group (COA).

Company Calendar

Last Earnings
11/19/2024
Today
3/30/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:FAB
CIK
N/A
Fax
N/A
Employees
48
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-4,103,138.16
Net Margins
-195.95%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£2.09 million
Cash Flow
GBX 0.73 per share
Price / Cash Flow
9.02
Book Value
GBX 3.51 per share
Price / Book
1.88

Miscellaneous

Free Float
N/A
Market Cap
£6.23 million
Optionable
Not Optionable
Beta
0.49
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (LON:FAB) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners